Sunday, November 30, 2025 11:35:11 PM
ASw,
Thanks for asking 😶
No, longs are not concerned with tin foil hat conspiracy theories…
The dendritic cell vaccine platforms at Roswell Park & UCLA have been supported substantially by U.S. federal funding. U.S. NIH 🇺🇸 & U.S. Department of Defense 🇺🇸 peer-reviewed grants have together provided tens of millions of dollars to advance DC platform technologies into clinical trials.
DCVax-L & GBM are no longer the only platform & indication awaiting submission for FDA review. The required automation technology is just now catching up, combos are in play & have reached PII, & we now have multiple platforms/combos that will be candidates for FDA review too. Ironically, slow developments have evolved rapidly in recent years!
Standardized automated manufacturing is the key to regulatory approval in multiple countries, especially for novel cell-based products like DC vaccines.
DCVax-L, DCVax-Direct, & the Roswell aDC1 platform are all pipeline candidates on clear clinical development pathways advancing toward 🇺🇸 U.S. FDA review.
Thanks for asking 😶
No, longs are not concerned with tin foil hat conspiracy theories…
The dendritic cell vaccine platforms at Roswell Park & UCLA have been supported substantially by U.S. federal funding. U.S. NIH 🇺🇸 & U.S. Department of Defense 🇺🇸 peer-reviewed grants have together provided tens of millions of dollars to advance DC platform technologies into clinical trials.
DCVax-L & GBM are no longer the only platform & indication awaiting submission for FDA review. The required automation technology is just now catching up, combos are in play & have reached PII, & we now have multiple platforms/combos that will be candidates for FDA review too. Ironically, slow developments have evolved rapidly in recent years!
Standardized automated manufacturing is the key to regulatory approval in multiple countries, especially for novel cell-based products like DC vaccines.
DCVax-L, DCVax-Direct, & the Roswell aDC1 platform are all pipeline candidates on clear clinical development pathways advancing toward 🇺🇸 U.S. FDA review.
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
